Skip to main content

iShares Evolved U.S. Innovative Healthcare ETF (IEIH)

BATS: IEIH · IEX Real-Time Price · USD
0.00 (0.00%)
After-hours:Oct 22, 2021 8:00 PM EDT
-0.07 (-0.21%)
At close: Oct 22, 4:00 PM
Expense Ratio0.18%
PE Ratio29.38
Shares Out1.20M
Dividend (ttm)$0.97
Dividend Yield2.79%
Ex-Dividend DateSep 24, 2021
1-Year Return
Previous Close34.90
Day's Range34.63 - 34.98
52-Week Low27.72
52-Week High37.52
Inception DateMar 21, 2018

About IEIH

The investment seeks to provide access to U.S. companies with innovative healthcare exposure, as classified using a proprietary classification system. The fund invests, under normal circumstances, at least 80% of its net assets in U.S. listed common stock of large-, mid- and small-capitalization pharmaceutical and biotechnology companies. It will hold common stock of those companies that fall into the Innovative Healthcare Evolved Sector which have economic characteristics that have been historically correlated with companies traditionally defined as pharmaceutical and biotechnology companies. The fund is non-diversified.

Asset ClassEquity
RegionNorth America
IssuerBlackRock iShares
Stock ExchangeBATS
Ticker SymbolIEIH
Index TrackedMSCI USA IMI Health Care Index

Top 10 Holdings

56.36% of assets
Johnson & JohnsonJNJ9.34%
Eli LillyLLY6.04%
Gilead SciencesGILD4.30%
Bristol-Myers SquibbBMY4.02%
Regeneron PharmaceuticalsREGN3.59%
View More Holdings


Ex-DividendAmountPay Date
Sep 24, 2021$0.12464Sep 30, 2021
Jun 10, 2021$0.08647Jun 16, 2021
Mar 25, 2021$0.10641Mar 31, 2021
Dec 14, 2020$0.09933Dec 18, 2020
Sep 23, 2020$0.09635Sep 29, 2020
Jun 15, 2020$0.0631Jun 19, 2020
Full Dividend History


Take a Look at the Top-Performing Biotech ETFs YTD

The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.

3 weeks ago - Zacks Investment Research

Should Investors Follow Private Equity into Life Sciences?

Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new fun...

2 months ago - GuruFocus

Pharma & Healthcare ETFs at a One-Year High: Here's Why

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

2 months ago - Zacks Investment Research

Time for Pharma and Healthcare ETFs?

The broader medical sector should gain on decent earnings expectations and higher COVID-19-related sales

3 months ago - Zacks Investment Research

2 Sector ETFs Hovering Around All-Time Highs

The U.S. economic backdrop and investors' sentiments have remained mixed in recent weeks.

3 months ago - Zacks Investment Research

How To Legally Dodge Biden's Capital Gains Tax In Your Portfolio

Biden's proposal to nearly double the capital gains tax rate is unnerving investors. But there's a legal way to dodge them.

5 months ago - Investors Business Daily

Biotech ETFs Make Gains Tuesday, Despite the J&J Vaccine Pause

Some biotech and pharmaceutical ETFs are gaining on Tuesday despite news that Johnson and Johnson's coronavirus vaccine has been halted in over two dozen states, after the Food and Drug Administration r...

Other symbols:BBHFHLCIHE
6 months ago - ETF Trends

ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.

Other symbols:FDLFTXHIHE
6 months ago - Zacks Investment Research

ETFs to Shine as Pfizer's COVID-19 Vaccine Gets a Nod in Europe

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.

10 months ago - Zacks Investment Research

ETF Tax Benefits Continued In 2020

Capital gains are rare in the ETF space, but there are always some.

11 months ago - ETFcom

Wanna Be a Value Investor? Follow Buffett & Play 2 ETF Areas

Warren Buffett took positions in Biogen and Kroger. Investors who want to follow Buffett's picking of these two value stocks can also play these ETFs as well.

1 year ago - Zacks Investment Research

JNJ Beats, Ups View: Healthcare ETFs to Buy

Johnson & Johnson continued its long streak of earnings beat and outpaced revenue estimates. It also raised its guidance for the full year.

Other symbols:IHEIYHVHTXLV
2 years ago - Zacks Investment Research

Amgen to Buy Celgene's Otezla: 5 ETF Drugs

Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.

Other symbols:BBHIBBPBEPJP
2 years ago - Zacks Investment Research

Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat

Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.

Other symbols:IHEIYHVHTXLV
2 years ago - Zacks Investment Research